Revenue
2014
2015
2016
2020
2021
2022
2023
2025
CRESCENT BIOPHARMA, INC. (CBIO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | — | $10,000 | $75,000 | $1.2M | $10.2M | — | — | — | $18,500 | $20.1M | $15.0M | $4.0M | $15.3M |
| Research & development | $138.1M | $14.3M | $20.1M | $28.4M | $47.5M | $44.9M | $47.0M | $40.1M | $24.1M | $23.3M | $25.1M | $19.6M | $11.7M | $9.4M |
| Operating expenses | $163.5M | $40.0M | $39.3M | $47.5M | $64.6M | $61.7M | $61.4M | $51.5M | $33.9M | $31.9M | $32.9M | $26.2M | $14.6M | $11.6M |
| Operating income | −$152.6M | −$40.0M | −$39.3M | −$47.4M | −$63.4M | −$51.5M | −$61.4M | −$51.5M | −$33.9M | −$31.9M | −$12.8M | −$11.1M | −$10.6M | $3.6M |
| Net income | −$153.9M | −$37.9M | −$36.9M | −$46.7M | −$63.4M | −$51.0M | −$57.9M | −$48.3M | −$33.3M | −$31.8M | −$12.8M | −$11.1M | −$10.6M | $3.7M |
| Basic EPSper diluted share | — | -$0.59 | -$0.58 | -$0.89 | -$1.23 | -$1.12 | -$1.34 | -$1.18 | -$1.13 | -$1.50 | -$0.67 | -$0.60 | -$8.87 | $3.93 |
| Diluted EPSper diluted share | — | -$0.59 | -$0.58 | -$0.89 | -$1.23 | -$1.12 | -$1.34 | -$1.18 | -$1.13 | -$1.50 | -$0.67 | -$0.60 | -$8.87 | $0.33 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Lynch RyanSee Remarks | SellOrdinary Shares | 465 | $17.99 | $8.4K | 13.9K |
| Jun 22, 2026Form 4 · 10b5-1 | Pinkas JanChief Scientific Officer | SellOrdinary Shares | 1.3K | $17.99 | $23.2K | 22.2K |
| Jun 22, 2026Form 4 · 10b5-1 | Scalzo Richard WilliamChief Financial Officer | SellOrdinary Shares | 1.1K | $17.99 | $20.0K | 20.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Bispham Barbara HarlinSee Remarks | SellOrdinary Shares | 1.2K | $17.99 | $21.9K | 19.3K |
| Jun 22, 2026Form 4 · 10b5-1 | Im Ellie EunkyungChief Medical Officer | SellOrdinary Shares | 1.2K | $17.99 | $21.9K | 22.1K |